Andrew Huberman· PhD
The doses that I take, I take such a high dose that if I were to get your kidney transplanted into me, my immune system wouldn't notice your kidney in my body. I mean, that's the level of dose I take.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
The doses that I take, I take such a high dose that if I were to get your kidney transplanted into me, my immune system wouldn't notice your kidney in my body. I mean, that's the level of dose I take.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
so it's really not clear to what extent rapamycin as a mono therapy in healthy people has immunosuppressive properties and the data in mice I would say is mixed it really seems to be the case then for some forms of a Mian challenge at high doses rapamycin can enhance susceptibility to infection for other forms of immune challenge and enhances function but again those studies are almost always done at very high doses of the drug that are even much higher than you would give to a person so it's it's an unknown
there are clearly short-term studies that demonstrate that the differential dosing pattern of rapid Amy can actually produce immune augmentation and immune enhancement rather than immune suppression
we don't know that about rap ay yet um but I think it ought to be a high priority to find out what lowd do rap ay does
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.